Paper Details

  1. Home
  2. Paper Details

Safety of the 15-valent pneumococcal conjugate vaccine: A phase I clinical trial.

Author: DuLin, FangWen-Jian, GaoZhao, JiWen-Juan, LiMin-Jie, PanLu-Lu, ZhaoYing, ZhaoYu-Liang, ZhouWei-Wei

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This phase I clinical trial evaluated the safety of the 15-valent pneumococcal conjugate vaccine (PCV15) in infants. The vaccine was generally well-tolerated, with most side effects being mild and transient, primarily fever and pain at the injection site. One case of hypersensitivity was reported.
Paper Details　
Original Abstract of the Article :
To evaluate the safety of the 15-valent pneumococcal conjugate vaccine (PCV15 (by LvZhu & Co. Ltd)) in healthy infants aged 2 months (minimum to 6 weeks) and 3 months old. This phase I clinical trial enrolled 80 subjects in Laishui County, Hebei Province, China. The total population was divided into...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746401/

データ提供：米国国立医学図書館（NLM）

Safety First: A Phase I Trial of the 15-valent Pneumococcal Conjugate Vaccine

Protecting our little ones from infectious diseases is a top priority for parents and healthcare providers. Vaccines play a vital role in this endeavor, and the development of new, multi-valent vaccines is a constant pursuit. This phase I clinical trial meticulously assessed the safety of a new 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants. Researchers carefully enrolled infants of different ages and administered the vaccine according to different schedules. The primary focus was to monitor for any adverse events (AEs) or serious adverse events (SAEs) related to the vaccine. The results showed that PCV15 was generally well tolerated in infants, with most AEs being mild and transient. The study provides valuable evidence supporting the safety of this new vaccine.

A Safe and Effective Shield for Young Ones

The results of this phase I trial offer reassurance about the safety of PCV15 in infants. The data indicates that this new vaccine is generally well tolerated and holds promise for protecting young children from pneumococcal infections.

Staying Informed and Protected

As parents, it's important to stay informed about the latest recommendations regarding vaccinations. Consulting with your child's pediatrician is essential to determine the appropriate vaccination schedule and address any concerns. Remember, just as a camel needs protection from the harsh desert environment, our children need the shield of vaccinations to stay healthy and strong.

Dr. Camel's Conclusion

The development of new vaccines is like finding a hidden oasis in the vast desert of infectious diseases. This research provides valuable evidence about the safety of a new vaccine, offering hope and protection for our little ones. By staying informed and consulting with healthcare professionals, we can ensure that our children are equipped with the best possible defenses against harmful diseases.

Date :
  1. Date Completed 2022-12-16
  2. Date Revised 2022-12-21
Further Info :

Pubmed ID

36121914

DOI: Digital Object Identifier

PMC9746401

Related Literature

Article Analysis
・Side Effects of pneumococcal conjugate vaccine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.